The Impact of China's Human Genetic Resources Regime on Biopharma MNCs

May 14, 2021 | BY

Vincent Chow

China's HGR regime has been significantly bolstered in the last two years, delaying the research and development activities of biopharma MNCs in the country

Nikita G. Sidorov/iStockphoto.com

This premium content is reserved for
China Law & Practice Subscribers.

  • A database of over 3,000 essential documents including key PRC legislation translated into English
  • A choice of newsletters to alert you to changes affecting your business including sector specific updates
  • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected]